MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.

导出 OA

翻译打印收藏纠错

第一作者： Xiaochen,Zhai

第一单位： Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University Suzhou 215123, P. R. China.

作者： Xiaochen,Zhai ^[1] ; Fengtao,You ^[2] ; Shufen,Xiang ^[2] ; Licui,Jiang ^[2] ; Dan,Chen ^[1] ; Yafen,Li ^[2] ; Shuangshuang,Fan ^[1] ; Zhichao,Han ^[1] ; Tingting,Zhang ^[1] ; Gangli,An ^[1] ; Bozhen,Zhang ^[2] ; Yusheng,Chen ^[2] ; Huimin,Meng ^[1] ; Lin,Yang ^[3]

作者单位： Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University Suzhou 215123, P. R. China. ^[1] PersonGen BioTherapeutics (Suzhou) Co., Ltd. Suzhou 215123, P. R. China. ^[2] Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University Suzhou 215123, P. R. China.;PersonGen BioTherapeutics (Suzhou) Co., Ltd. Suzhou 215123, P. R. China. ^[3]

关键词 MUC1-Tn Vγ9Vδ2 T cells cancer immunotherapy chimeric antigen receptor

PMID 33520361

发布时间 2021-02-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交